US FDA delays Feraheme sNDA verdict, but shares rise
This article was originally published in Scrip
Executive Summary
Someone forgot to tell investors on 17 October the US FDA had postponed its decision by three months on expanding the use of AMAG Pharmaceuticals’ iron replacement product Feraheme (ferumoxytol) injection for intravenous (IV) use.